US Diabetes Care Market Size & Trend Analysis | 2025-2031
The U.S. diabetes monitoring, treatment and drug delivery market was valued at nearly $48 billion in 2024 and is expected to grow to $79 billion by 2031.| iData Research
The U.S. diabetes monitoring, treatment and drug delivery market was valued at nearly $48 billion in 2024 and is expected to grow to $79 billion by 2031.| iData Research
US FDA approved Novo Nordisk to use their GLP-1 drug, Ozempic, to reduce the risk of kidney failure and kidney disease progression.| iData Research
The continuous glucose monitoring market has experienced strong but slowing growth in the U.S. blood glucose monitoring sector.| idataresearch.com
